{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:16:24Z","timestamp":1790396184692,"version":"4.1.0"},"reference-count":152,"publisher":"Elsevier BV","issue":"10-13","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.1016\/j.steroids.2003.08.007","type":"journal-article","created":{"date-parts":[[2003,10,9]],"date-time":"2003-10-09T05:21:59Z","timestamp":1065676919000},"page":"981-993","source":"Crossref","is-referenced-by-count":95,"title":["Progesterone antagonists and progesterone receptor modulators: an overview"],"prefix":"10.1016","volume":"68","author":[{"given":"Irving M","family":"Spitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2003.08.007_BIB1","unstructured":"Philibert D, Deraedt R, Teutsch G. RU 38486: a potent antiglucocorticoid in vivo. In: Proceedings of the VII International Congress of Pharmacology, Tokyo, Japan; 1981."},{"key":"10.1016\/j.steroids.2003.08.007_BIB2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev.pa.36.040196.000403","article-title":"Antiprogestins: mechanism of action and contraceptive potential","volume":"36","author":"Spitz","year":"1996","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB3","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1128\/MCB.18.3.1369","article-title":"The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor","volume":"18","author":"Wagner","year":"1998","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB4","doi-asserted-by":"crossref","first-page":"7940","DOI":"10.1073\/pnas.122225699","article-title":"Coactivator\/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486","volume":"99","author":"Liu","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.steroids.2003.08.007_BIB5","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1177\/153537020222701104","article-title":"Mechanism of action of progesterone antagonists","volume":"227","author":"Leonhardt","year":"2002","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.steroids.2003.08.007_BIB6","first-page":"291","article-title":"The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene","volume":"54","author":"Giangrande","year":"1999","journal-title":"Recent Prog. Horm. Res."},{"key":"10.1016\/j.steroids.2003.08.007_BIB7","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0039-128X(00)00194-X","article-title":"Progesterone receptor modulators and progesterone antagonists in women\u2019s health","volume":"65","author":"Spitz","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2003.08.007_BIB8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0039-128X(00)00186-0","article-title":"Preface","volume":"65","author":"Spitz","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2003.08.007_BIB9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0039-128X(00)00178-1","article-title":"Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity","volume":"65","author":"Elger","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2003.08.007_BIB10","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/nar\/19.6.1227","article-title":"Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells","volume":"19","author":"Klein Hitpass","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.steroids.2003.08.007_BIB11","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1210\/en.139.4.1905","article-title":"The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation","volume":"139","author":"Gass","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2003.08.007_BIB12","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1126\/science.270.5240.1354","article-title":"Sequence and characterization of a coactivator for the steroid hormone receptor superfamily","volume":"270","author":"Onate","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.steroids.2003.08.007_BIB13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1113\/jphysiol.1934.sp003217","volume":"83","author":"McPhail","year":"1934","journal-title":"J. Physiol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB14","doi-asserted-by":"crossref","unstructured":"Philibert D. RU38486: an original multifaceted antihormone in vivo. In: Agarwal M, editor. Adrenal steroid antagonism. Berlin: Walter de Gruyter and Co.; 1984. p. 77\u2013101.","DOI":"10.1515\/9783110809572-004"},{"key":"10.1016\/j.steroids.2003.08.007_BIB15","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1021\/jm001000c","article-title":"Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist","volume":"43","author":"Fuhrmann","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2003.08.007_BIB16","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.1016\/S0021-9258(18)98344-4","article-title":"Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP","volume":"268","author":"Sartorius","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.steroids.2003.08.007_BIB17","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1073\/pnas.90.10.4441","article-title":"The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways","volume":"90","author":"Beck","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.steroids.2003.08.007_BIB18","doi-asserted-by":"crossref","first-page":"8739","DOI":"10.1073\/pnas.93.16.8739","article-title":"16-Alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity","volume":"93","author":"Wagner","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.steroids.2003.08.007_BIB19","doi-asserted-by":"crossref","unstructured":"World Health Organisation task force on postovulatory methods of fertility regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ 1993;307:532\u20137.","DOI":"10.1136\/bmj.307.6903.532"},{"key":"10.1016\/j.steroids.2003.08.007_BIB20","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM200003303421307","article-title":"Medical termination of pregnancy","volume":"342","author":"Christin-Maitre","year":"2000","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.steroids.2003.08.007_BIB21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0029-7844(01)01462-4","article-title":"Mifepristone 100 mg in abortion regimens","volume":"98","author":"Creinin","year":"2001","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB22","doi-asserted-by":"crossref","unstructured":"World Health Organization task force on postovulatory methods for fertility regulation. Lowering the doses of mifepristone and gameprost for early abortion: a randomised controlled trial. BJOG 2001;108:738\u201342.","DOI":"10.1111\/j.1471-0528.2001.00171.x"},{"key":"10.1016\/j.steroids.2003.08.007_BIB23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1479-828X.1996.tb02915.x","article-title":"Termination of early human pregnancy with either 50 mg or 200 mg single oral dose of mifepristone (RU486) in combination with either 0.5 mg or 1.0 mg vaginal gemeprost","volume":"36","author":"Prasad","year":"1996","journal-title":"Aust. NZJ Obstet. Gynaecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0029-7844(97)00111-7","article-title":"Absorption kinetics of misoprostol with oral or vaginal administration","volume":"90","author":"Zieman","year":"1997","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/13625180008500394","article-title":"A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion","volume":"5","author":"Aubeny","year":"2000","journal-title":"Eur. J. Contracept. Reprod. Health Care"},{"key":"10.1016\/j.steroids.2003.08.007_BIB26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0010-7824(01)00229-3","article-title":"Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion","volume":"64","author":"Schaff","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.steroids.2003.08.007_BIB27","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/humrep\/17.7.1738","article-title":"Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation","volume":"17","author":"Tang","year":"2002","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB28","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1471-0528.2002.01075.x","article-title":"Medical management of early fetal demise using sublingual misoprostol","volume":"109","author":"Wagaarachchi","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.steroids.2003.08.007_BIB29","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1001\/jama.284.15.1948","article-title":"Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial","volume":"284","author":"Schaff","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2003.08.007_BIB30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0306-5456(00)00117-0","article-title":"Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial","volume":"108","author":"Creinin","year":"2001","journal-title":"BJOG"},{"key":"10.1016\/j.steroids.2003.08.007_BIB31","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/humrep\/17.6.1477","article-title":"A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy","volume":"17","author":"Jain","year":"2002","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0010-7824(98)00150-4","article-title":"Low-dose mifepristone 200 mg and vaginal misoprostol for abortion","volume":"59","author":"Schaff","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.steroids.2003.08.007_BIB33","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/humrep\/16.10.2098","article-title":"Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation","volume":"16","author":"Bartley","year":"2001","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB34","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM199804303381801","article-title":"Early pregnancy termination with mifepristone and misoprostol in the United States","volume":"338","author":"Spitz","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 2","key":"10.1016\/j.steroids.2003.08.007_BIB35","first-page":"85","article-title":"Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol","volume":"40","author":"Aubeny","year":"1995","journal-title":"Int. J. Fertil."},{"key":"10.1016\/j.steroids.2003.08.007_BIB36","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1093\/humrep\/13.10.2962","article-title":"An effective regimen for early medical abortion: a report of 2000 consecutive cases","volume":"13","author":"Ashok","year":"1998","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB37","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJM199504133321502","article-title":"Induction of abortion with mifepristone (RU486) and oral or vaginal misoprostol","volume":"332","author":"El-Rafeay","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2003.08.007_BIB38","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/HUMREP\/10.6.1521","article-title":"Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion","volume":"10","author":"Baird","year":"1995","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0010-7824(96)00252-1","article-title":"The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation, UK multicentre study: final results","volume":"55","author":"Urquhart","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.steroids.2003.08.007_BIB40","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1046\/j.1471-0528.2002.02156.x","article-title":"Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases","volume":"109","author":"Ashok","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.steroids.2003.08.007_BIB41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/humrep\/16.1.67","article-title":"A comparative study of surgical and medical procedures: 932 pregnancy terminations up to 63 days gestation","volume":"16","author":"Child","year":"2001","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0010-7824(00)00187-6","article-title":"Parity is a major determinant of success rate in medical abortion: a retrospective analysis of 3161 consecutive cases of early medical abortion treated with reduced doses of mifepristone and vaginal gemeprost","volume":"62","author":"Bartley","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.steroids.2003.08.007_BIB43","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1046\/j.1471-0528.2002.01462.x","article-title":"A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy","volume":"109","author":"Bartley","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.steroids.2003.08.007_BIB44","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1471-0528.1999.tb08371.x","article-title":"Non-surgical mid-trimester termination of pregnancy: a review of 500 consecutive cases","volume":"106","author":"Ashok","year":"1999","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB45","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1093\/humrep\/15.10.2205","article-title":"Randomized comparison of vaginal (200 \u03bcg every 3 h) and oral (400 \u03bcg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy","volume":"15","author":"Ngai","year":"2000","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(01)00219-0","article-title":"Second trimester medical abortion with mifepristone and gemeprost: a review of 956 cases","volume":"64","author":"Tang","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.steroids.2003.08.007_BIB47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0010-7824(93)90133-R","article-title":"Clinical pharmacology of RU486: an antiprogestin and antiglucocorticoid","volume":"48","author":"Spitz","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/j.steroids.2003.08.007_BIB48","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/humrep\/17.1.92","article-title":"A randomized comparison of medical abortion and surgical vacuum aspiration at 10\u201313 weeks gestation","volume":"17","author":"Ashok","year":"2002","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB49","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1471-0528.1999.tb08320.x","article-title":"Medical termination of pregnancy at 63\u201383 days gestation","volume":"106","author":"Gouk","year":"1999","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB50","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1067\/mob.2003.267","article-title":"Medical abortion at 64 to 91 days of gestation: a review of 483 consecutive cases","volume":"188","author":"Hamoda","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB51","doi-asserted-by":"crossref","unstructured":"World Health Organization task force on postovulatory methods of fertility regulation. Menstrual regulation by mifepristone plus prostaglandin: results from a multicentre trial. Hum Reprod 1995;10:308\u201314.","DOI":"10.1093\/oxfordjournals.humrep.a135933"},{"key":"10.1016\/j.steroids.2003.08.007_BIB52","unstructured":"Neilson JP, Neilson JP. Mifepristone for induction of labour (Cochrane Review). The Cochrane Library, Issue 1. Oxford: Update Software; 2003."},{"key":"10.1016\/j.steroids.2003.08.007_BIB53","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0029-7844(98)00284-1","article-title":"The effects of mifepristone on cervical ripening and labor induction in primigravidae","volume":"92","author":"Elliott","year":"1998","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB54","first-page":"972","article-title":"Labor induction in women at term with mifepristone (RU486): a double-blind, randomized, placebo-controlled study","volume":"80","author":"Frydman","year":"1992","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0029-7844(98)00225-7","article-title":"Cervical ripening with mifepristone before labor induction: a randomized study","volume":"92","author":"Giacalone","year":"1998","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB56","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1471-0528.1994.tb13150.x","article-title":"Mifepristone for labour induction after previous caesarean section","volume":"101","author":"Lelaidier","year":"1994","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB57","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/j.1600-0412.1999.780910.x","article-title":"Induction of labor with mifepristone: a randomized, double-blind study versus placebo","volume":"78","author":"Stenlund","year":"1999","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.steroids.2003.08.007_BIB58","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0029-7844(00)00947-9","article-title":"Mifepristone for preinduction cervical ripening beyond 41 weeks\u2019 gestation: a randomized controlled trial","volume":"96","author":"Wing","year":"2000","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB59","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1471-0528.1990.tb01827.x","article-title":"The placental transfer of mifepristone (RU486) during the second trimester and its influence upon maternal and fetal steroid concentrations","volume":"97","author":"Hill","year":"1990","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB60","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0301-2115(00)00506-6","article-title":"The effects of mifepristone on uterine sensitivity to oxytocin and on fetal heart rate patterns","volume":"97","author":"Giacalone","year":"2001","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB61","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/oxfordjournals.humrep.a138078","article-title":"Mifepristone (RU486) induces embryo expulsion in first trimester non-developing pregnancies: a prospective randomized trial","volume":"8","author":"Lelaidier","year":"1993","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB62","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0010-7824(01)00200-1","article-title":"Mifepristone and misoprostol for early abortion when no gestational sac is present","volume":"63","author":"Schaff","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.steroids.2003.08.007_BIB63","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1471-0528.1996.tb09632.x","article-title":"The costs of treating miscarriage: a comparison of medical and surgical management","volume":"103","author":"Hughes","year":"1996","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB64","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/bmj.305.6866.1399","article-title":"Medical management of missed abortion and anembryonic pregnancy","volume":"305","author":"El-Rafeay","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.steroids.2003.08.007_BIB65","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/humrep\/16.9.1849","article-title":"Medical management of early fetal demise using a combination of mifepristone and misoprostol","volume":"16","author":"Wagaarachchi","year":"2001","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB66","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1471-0528.1997.tb12075.x","article-title":"Unsuccessful treatment of missed abortion with a combination of an antiprogesterone and a prostaglandin E1 analogue","volume":"104","author":"Nielsen","year":"1997","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB67","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1080\/j.1600-0412.2002.811111.x","article-title":"Management of missed abortion: comparison of medical treatment with either mifepristone + misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen county, Denmark","volume":"81","author":"Gronlund","year":"2002","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.steroids.2003.08.007_BIB68","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0140-6736(95)90060-8","article-title":"Expectant management of first-trimester spontaneous abortion","volume":"345","author":"Nielsen","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2003.08.007_BIB69","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(85)90575-6","article-title":"Induction of labour with mifepristone after intrauterine fetal death","volume":"2","author":"Cabrol","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2003.08.007_BIB70","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/0002-9378(90)91193-G","article-title":"Induction of labor with mifepristone (RU486) in intrauterine fetal death","volume":"163","author":"Cabrol","year":"1990","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB71","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1471-0528.2002.01238.x","article-title":"Medical management of late intrauterine death using a combination of mifepristone and misoprostol","volume":"109","author":"Wagaarachchi","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.steroids.2003.08.007_BIB72","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1365-2265.1997.1290951.x","article-title":"Effect of mifepristone on folliculogenesis in women treated with recombinant FSH","volume":"46","author":"Messinis","year":"1997","journal-title":"Clin. Endocrinol. Oxf."},{"key":"10.1016\/j.steroids.2003.08.007_BIB73","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1742-1241.2002.tb11212.x","article-title":"The potential of mifepristone (RU486) as a female contraceptive drug","volume":"56","author":"Sarkar","year":"2002","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.steroids.2003.08.007_BIB74","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1210\/en.131.5.2446","article-title":"Luteal control of endometrial receptivity and its modification by progesterone antagonists","volume":"131","author":"Hegele Hartung","year":"1992","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2003.08.007_BIB75","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0015-0282(97)81918-8","article-title":"Potential enhancement of endometrial receptivity in cycles using controlled ovarian hyperstimulation with antiprogestins: a hypothesis","volume":"67","author":"Paulson","year":"1997","journal-title":"Fertil. Steril."},{"issue":"Suppl 1","key":"10.1016\/j.steroids.2003.08.007_BIB76","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/humrep\/9.suppl_1.77","article-title":"Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models","volume":"9","author":"Hodgen","year":"1994","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB77","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/humrep\/13.2.269","article-title":"Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct","volume":"13","author":"Slayden","year":"1998","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB78","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1210\/jc.78.2.440","article-title":"RU486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (Macaca mulatta)","volume":"78","author":"Slayden","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2003.08.007_BIB79","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/humrep\/deg022","article-title":"Effect of long-term treatment with low-dose mifepristone on the endometrium","volume":"18","author":"Baird","year":"2003","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB80","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1210\/jc.81.5.1933","article-title":"Antiprogestin and\/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study","volume":"81","author":"Grow","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2003.08.007_BIB81","doi-asserted-by":"crossref","first-page":"11945","DOI":"10.1016\/S0021-9258(17)32664-9","article-title":"RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism","volume":"269","author":"McDonnell","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.steroids.2003.08.007_BIB82","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/humrep\/13.2.259","article-title":"Chronic treatment of female rhesus monkeys with low doses of the antiprogestin ZK 137 316: establishment of a regimen that permits normal menstrual cyclicity","volume":"13","author":"Zelinski Wooten","year":"1998","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB83","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0039-128X(00)00190-2","article-title":"Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium","volume":"65","author":"Chwalisz","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2003.08.007_BIB84","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1083\/jcb.125.2.393","article-title":"Progesterone-dependent expression of keratinocyte growth factor mRNA in stromal cells of the primate endometrium: keratinocyte growth factor as a progestomedin","volume":"125","author":"Koji","year":"1994","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB85","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0015-0282(98)00029-6","article-title":"Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: a 1-year primate study on contraception and amenorrhea","volume":"69","author":"Grow","year":"1998","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.steroids.2003.08.007_BIB86","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/humrep\/12.6.1280","article-title":"Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo","volume":"12","author":"Greb","year":"1997","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB87","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0960-0760(96)00113-6","article-title":"Endometrial effects of RU486 in primates: antiproliferative action despite signs of estrogen action and increased cyclin-B expression","volume":"59","author":"Heikinheimo","year":"1996","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB88","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1172\/JCI117551","article-title":"Antioxidant: a new role for RU486 and related compounds","volume":"94","author":"Parthasarathy","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.steroids.2003.08.007_BIB89","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/oxfordjournals.humrep.a019433","article-title":"Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of postreceptor proliferative mechanisms","volume":"11","author":"Neulen","year":"1996","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB90","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1530\/rep.0.1240167","article-title":"Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor","volume":"124","author":"Brenner","year":"2002","journal-title":"Reproduction"},{"key":"10.1016\/j.steroids.2003.08.007_BIB91","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/jc.2002-021763","article-title":"Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium","volume":"88","author":"Slayden","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2003.08.007_BIB92","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1210\/jc.83.11.4092","article-title":"Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment","volume":"83","author":"Englund","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2003.08.007_BIB93","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0002-9378(93)90135-6","article-title":"Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas","volume":"169","author":"Brandon","year":"1993","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB94","unstructured":"Yen SSC. Use of antiprogestins in the management of endometriosis and leiomyoma. In: Donaldson MS, Dorflinger L, Brown SS, Benet LZ, editors. Clinical applications of mifepristone (RU496) and other antiprogestins. Washington, DC: National Academy Press; 1993. p. 189\u2013209."},{"key":"10.1016\/j.steroids.2003.08.007_BIB95","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00001703-199406000-00012","article-title":"RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri","volume":"6","author":"Murphy","year":"1994","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB96","first-page":"624","article-title":"Treatment of uterine leimyoma by two different doses of mifepristone","volume":"31","author":"Yang","year":"1996","journal-title":"Chin. J. Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB97","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0029-7844(02)02511-5","article-title":"Low-dose mifepristone for uterine leiomyomata","volume":"101","author":"Eisinger","year":"2003","journal-title":"Obstet. Gynecol"},{"key":"10.1016\/j.steroids.2003.08.007_BIB98","first-page":"490","article-title":"A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone","volume":"33","author":"Zeng","year":"1998","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"10.1016\/j.steroids.2003.08.007_BIB99","first-page":"301A","article-title":"Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM)","volume":"10","author":"Chwalisz","year":"2003","journal-title":"J. Soc. Gynecol. Investig."},{"key":"10.1016\/j.steroids.2003.08.007_BIB100","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0015-0282(16)56214-1","article-title":"Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist","volume":"60","author":"Kettel","year":"1993","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.steroids.2003.08.007_BIB101","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0015-0282(16)58022-4","article-title":"Treatment of endometriosis with the antiprogesterone mifepristone (RU486)","volume":"65","author":"Kettel","year":"1996","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.steroids.2003.08.007_BIB102","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0002-9378(98)70316-3","article-title":"Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU486)","volume":"178","author":"Kettel","year":"1998","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB103","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1210\/jc.2002-020876","article-title":"RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway","volume":"88","author":"Han","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2003.08.007_BIB104","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jcem-61-3-536","article-title":"Successful treatment of Cushing\u2019s syndrome with the glucocorticoid antagonist RU486","volume":"61","author":"Nieman","year":"1985","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2003.08.007_BIB105","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1210\/jc.86.8.3568","article-title":"Successful long-term treatment of refractory Cushing\u2019s disease with high-dose mifepristone (RU486)","volume":"86","author":"Chu","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2003.08.007_BIB106","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1056\/NEJM199308053290607","article-title":"Mifepristone (RU486): a modulator of progestin and glucocorticoid action","volume":"329","author":"Spitz","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2003.08.007_BIB107","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.4049\/jimmunol.169.11.6361","article-title":"HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection","volume":"169","author":"Mirani","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB108","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.ne.02.030179.000433","article-title":"The brain as a target for steroid hormone action","volume":"2","author":"McEwen","year":"1979","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.steroids.2003.08.007_BIB109","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1212\/WNL.58.9.1436","article-title":"Mifepristone (RU486) for Alzheimer\u2019s disease","volume":"58","author":"Pomara","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.steroids.2003.08.007_BIB110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12031-002-0033-3","article-title":"Slowing the progression of cognitive decline in Alzheimer\u2019s disease using mifepristone","volume":"19","author":"Belanoff","year":"2002","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.steroids.2003.08.007_BIB111","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0006-3223(02)01432-4","article-title":"An open label trial of C-1073 (mifepristone) for psychotic major depression","volume":"52","author":"Belanoff","year":"2002","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.steroids.2003.08.007_BIB112","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/00004714-200110000-00009","article-title":"Rapid reversal of psychotic depression using mifepristone","volume":"21","author":"Belanoff","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.steroids.2003.08.007_BIB113","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S0306-4530(97)00021-8","article-title":"Antiglucocorticoid therapies in major depression: a review","volume":"22","author":"Pearson Murphy","year":"1997","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.steroids.2003.08.007_BIB114","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0039-128X(00)00195-1","article-title":"Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer","volume":"65","author":"Klijn","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2003.08.007_BIB115","first-page":"455","article-title":"The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial","volume":"74","author":"Romieu","year":"1987","journal-title":"Bull Cancer"},{"key":"10.1016\/j.steroids.2003.08.007_BIB116","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.1996.14.10.2709","article-title":"Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study","volume":"14","author":"Perrault","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB117","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0960-0760(90)90421-G","article-title":"Treatment of breast cancer with different antiprogestins: preclinical and clinical studies","volume":"37","author":"Bakker","year":"1990","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB118","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3171\/jns.1991.74.6.0861","article-title":"Treatment of unresecatable meningiomas with the antipprogesterone agent mifepristone","volume":"74","author":"Grunberg","year":"1991","journal-title":"J. Neurosurg."},{"issue":"Suppl 1","key":"10.1016\/j.steroids.2003.08.007_BIB119","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/humrep\/9.suppl_1.202","article-title":"Role of antiprogestational therapy for meningiomas","volume":"9","author":"Grunberg","year":"1994","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB120","unstructured":"Grunberg SM, Rankin C, Townsend J, Ahamadi J, Feun L, Fredricks R, et al. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. San Francisco, CA. Am Soc Clin Oncol 2001;20."},{"key":"10.1016\/j.steroids.2003.08.007_BIB121","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1006\/gyno.2000.5789","article-title":"Phase II study of mifepristone (RU486) in refractory ovarian cancer","volume":"77","author":"Rocereto","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB122","doi-asserted-by":"crossref","unstructured":"UK Multicenter Study Group. Oral mifepristone 600 mg and vaginal gemeprost for mid-trimester induction of abortion. An open multicenter study. Contraception 1997;56:361\u20136.","DOI":"10.1016\/S0010-7824(97)00184-4"},{"key":"10.1016\/j.steroids.2003.08.007_BIB123","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0301-2115(95)02365-8","article-title":"Uterine rupture during second trimester termination of pregnancy using mifepristone and a prostaglandin","volume":"65","author":"Phillips","year":"1996","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB124","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1471-0528.1995.tb09142.x","article-title":"Uterine rupture during therapeutic abortion in the second trimester using mifepristone and prostaglandin","volume":"102","author":"Norman","year":"1995","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB125","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/344464","article-title":"Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease","volume":"35","author":"Sinave","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.steroids.2003.08.007_BIB126","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0140-6736(97)12363-7","article-title":"Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy","volume":"351","author":"Gonzalez","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2003.08.007_BIB127","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajmg.1320470113","article-title":"Limb deficiency with or without Mobius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy","volume":"47","author":"Gonzalez","year":"1993","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.steroids.2003.08.007_BIB128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0140-6736(91)90046-R","article-title":"Misoprostol and congenital malformations","volume":"338","author":"Fonseca","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2003.08.007_BIB129","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJM199806253382604","article-title":"Use of misoprostol during pregnancy and Mobius syndrome in infants","volume":"338","author":"Pastuszak","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2003.08.007_BIB130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/jcem-73-1-187","article-title":"The endocrine effects of long-term treatment with mifepristone (RU486)","volume":"73","author":"Lamberts","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2003.08.007_BIB131","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0026-0495(97)90256-0","article-title":"Alterations in the pituitary\u2013thyroid and pituitary\u2013adrenal axes\u2014consequences of long-term mifepristone treatment","volume":"46","author":"Heikinheimo","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.steroids.2003.08.007_BIB132","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1210\/en.135.5.1972","article-title":"The effects of hydrocortisone and RU486 (mifepristone) on iodide uptake in porcine thyroid cells in primary culture","volume":"135","author":"Takiyama","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2003.08.007_BIB133","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2265.1995.tb02610.x","article-title":"Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth","volume":"43","author":"Cameron","year":"1995","journal-title":"Clin. Endocrinol. Oxf."},{"key":"10.1016\/j.steroids.2003.08.007_BIB134","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0015-0282(16)57678-X","article-title":"Regression of uterine leiomyomata to the antiprogesterone RU486: dose\u2013response effect","volume":"64","author":"Murphy","year":"1995","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.steroids.2003.08.007_BIB135","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1210\/jc.76.2.513","article-title":"Regression of uterine leiomyomata in response to the antiprogesterone RU486","volume":"76","author":"Murphy","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2003.08.007_BIB136","first-page":"243","article-title":"Low-dose mifepristone for uterine leiomyomata","volume":"101","author":"Eisinger","year":"2003","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB137","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1210\/jcem-71-6-1474","article-title":"Effect of chronic treatment with the glucocorticoid antagonist RU486 in man: toxicity, immunological, and hormonal aspects","volume":"71","author":"Laue","year":"1990","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2003.08.007_BIB138","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/humupd\/4.5.570","article-title":"Modulation of oestrogenic effects by progesterone antagonists in the rat uterus","volume":"4","author":"Chwalisz","year":"1998","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.steroids.2003.08.007_BIB139","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0940-9602(11)80170-6","article-title":"Morphology of the rat uterus after long-term treatment with progesterone antagonists","volume":"175","author":"Rumpel","year":"1993","journal-title":"Anat. Anz."},{"key":"10.1016\/j.steroids.2003.08.007_BIB140","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0002-9378(94)90468-5","article-title":"Estrogenic effects of the antiprogestin onapristone (ZK98.299) in the rodent uterus","volume":"171","author":"Bigsby","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB141","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1365-2265.2001.01026.x","article-title":"Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia","volume":"54","author":"Newfield","year":"2001","journal-title":"Clin. Endocrinol. Oxf."},{"key":"10.1016\/j.steroids.2003.08.007_BIB142","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7863\/jum.2000.19.7.487","article-title":"Large endometrial polyp in a patient on long-term mifepristone therapy","volume":"19","author":"Martineau","year":"2000","journal-title":"J. Ultrasound Med."},{"key":"10.1016\/j.steroids.2003.08.007_BIB143","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0015-0282(16)57478-0","article-title":"Endometrial effects of long-term low-dose administration of RU486","volume":"63","author":"Murphy","year":"1995","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.steroids.2003.08.007_BIB144","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/humrep\/13.4.793","article-title":"Effects of long-term low-dose mifepristone on reproductive function in women","volume":"13","author":"Croxatto","year":"1998","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB145","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0039-128X(00)00196-3","article-title":"Alterations in sex steroids and gonadotropins in postmenopausal women subsequent to long-term mifepristone administration","volume":"65","author":"Heikinheimo","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2003.08.007_BIB146","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0960-0760(96)00178-1","article-title":"RU486 is a potent inhibitor of aromatase induction in human breast adipose tissue stromal cells","volume":"60","author":"Schmidt","year":"1997","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB147","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1210\/endo-118-4-1312","article-title":"Modulation of aromatase activity in human endometrial stromal cells by steroids","volume":"118","author":"Tseng","year":"1986","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2003.08.007_BIB148","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/oxfordjournals.humrep.a138022","article-title":"Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle","volume":"8","author":"Croxatto","year":"1993","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.steroids.2003.08.007_BIB149","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1073\/pnas.97.11.5936","article-title":"Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus","volume":"97","author":"Weihua","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.steroids.2003.08.007_BIB150","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1210\/en.140.12.5566","article-title":"The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens","volume":"140","author":"Hall","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2003.08.007_BIB151","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1210\/me.13.3.418","article-title":"Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen","volume":"13","author":"Zou","year":"1999","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.steroids.2003.08.007_BIB152","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1126\/science.289.5485.1751","article-title":"Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform","volume":"289","author":"Mulac-Jericevic","year":"2000","journal-title":"Science"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X03001727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X03001727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T22:31:38Z","timestamp":1704925898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X03001727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":152,"journal-issue":{"issue":"10-13","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["S0039128X03001727"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2003.08.007","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2003,11]]}}}